Clinical Development of Calcitriol and Calcitriol Analogs in Oncology: Progress and Considerations for Future Development

Vitamin D

Volumn 2, Issue , 2005, Pages 1741-1749

  Trump, Donald L ^a   Muindi, Josephia ^a   Johnson, Candace S ^a   Hershberger, Pamela A ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878523868     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012252687-9/50101-7     Document Type: Chapter

References (59)

1. Bikle DD, Pillai S Vitamin D, calcium, and epidermal differentiation. Endocr Rev 1993, 14(1):3-19.
2. Reichel H, Koeffler HP, Norman AW The role of vitamin D endocrine system in health and disease. N Engl J Med 1989, 320(15):980-991.
3. 3 analog in a squamous cell carcinoma model system. Mol Cell Diff 1995, 3(1):31-50.
4. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997, 50:999-1006.
5. 3 induced differentiation in a human maturation to macrophage-like cells. J Cell Biol 1984, 98:391-398.
6. Colston KW, Chander SK, Mackay AG, Coombes RC Effects of synthetic vitamin D analog on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992, 44:693-702.
7. 3. Cancer Res 1994, 54:4057-4064.
8. 3 on primary cultures of human prostatic cells. Cancer Res 1994, 54(3):805-810.
9. 3-induced apoptosis of murine squamous cell carcinoma cells: Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001, 276(28):26365-26373.
10. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 1990, 87(10):3929-3932.
11. Modzelewski RA Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumor cells in vitro. Proc Amer Assoc Cancer Res 1999, 40:580.
12. 3). Clin Cancer Res 2001, 7:1043-1051.
13. Light BW, Yu W-D, McElwain MC, Russell DM, Trump DL, Johnson CS Potentiation of cisplatin anti-tumor activity using a vitamin D analog in a murine squamous cell carcinoma model system. Cancer Res 1997, 57(17):3759-3764.
14. 3. Biochem J 1996, 316(Pt 2):361-371.
15. Kip1 in squamous cell carcinoma I response to 1,25-dihydroxycholecalciferol (calcitriol). Cancer Res 1999, 59:2644-2649.
16. 3-mediated anti-tumor activity with dexamethasone. J Natl Cancer Inst 1998, 90(2):134-141.
17. 3 with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 2001, 7:4165-4173.
18. Evans RM The steroid and thyroid hormone receptor superfamily. Science 1998, 240:889.
19. Darwish HM, DeLuca HF Recent advances in the molecular biology of vitamin D action. Progress in Nucleic Acid Research and Molecular Biology 1996, Vol 53:321. Academic Press Inc.
20. Darwish H, DeLuca HF Vitamin D-regulated gene expression. Critical Reviews in Eukaryotic Gene Expression 1993, 3(2):89-116.
21. Rustin GJ, Quinnell TG, Johnson J, Clarke H, Nelstrop AE, Bollag W Br J. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Cancer 1996, 74(9):1479-1481.
22. Slapak CA, Desforges JF, Fogaren T, Miller KB Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol 1992, 41(3):178-183.
23. 3 administration in acute nonlymphoid leukemia: pilot study. Haematologica 1991, 76(3):200-203.
24. 3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol 1990, 45(5):255-261.
25. Trouillas P, Honnorat J, Bret P, Jouvet A, Gerard JP Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long-term 1-alpha-hydroxycholecalciferol. J Neurooncol 2001, 51(1):57-66.
26. 3 on improving prognosis of osteosarcoma patients. Oncol Rep 2001, 8(2):321-324.
27. 3 (calcitriol). J Urol 1998, 159(6):2035-2039.
28. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995, 1:195-198.
29. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL A phase I trial of calcitriol (1,25-Dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999, 5:1339-1345.
30. Beer TM, Munar M, Henner WB A phase I trial of pulse calcitriol in patients with refractory malignancies. Cancer 2001, 91:2431-2439.
31. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL Pharmacokinetics of high-dose calcitriol: results obtained during a phase one trial of calcitriol and paclitaxel. Cancer Pharm Therap 2002, 72(6):648-659.
32. Muindi JR, Modezlewski RA, Peng Y, Hershberger PA, Trump DL, Johnson CS Pharmacokinetics of 1α,25-dihydroxycholecalciferol pharmacokinetics in normal and tumor-bearing mice. Oncology 2004, 66(1):62-66.
33. 3)+dexamethasone in androgen-independent prostate cancer (AIPC). Proceedings Amer Soc Clin Oncol 2000, 19:337a.
34. Beer TM, Lemmon D, Lowe BA, Henner WD High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003, 97(5):1217-1224.
35. 3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Therapeutics 2002, 1(10):821-829.
36. Gong JG, Constanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, Wang JY The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999, 399:806-809.
37. 3) on the pharmacokinetics of paclitaxel or carboplatin: results of two phase I studies. Proceedings Amer Soc Clin Oncol 2000, 19:210a.
38. Beer TM, Eilers KM, Garzotto M, Lowe BA, Henner WD Androgen-independent prostate cancer (AIPC) treatment with weekly high-dose calcitriol and docetaxel. Proceedings Amer Soc Clin Oncol 2002, 21:177a.
39. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003, 21(1):123-128.
40. Beer TM (personal communication).
41. Gulliford T, English J, Colston KW, Menday P, Moller S, Commbes RC A phase I study of the vitamin D analog EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998, 78(1):6-13.
42. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Bach Hansen J, Steward WP, Skov T, Burcharth F, Evans TR A phase II study of the vitamin D analog seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003, 89(2):252-257.
43. Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL A phase II trial of the vitamin D analog seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002, 86(5):680-685.
44. Sjoden G, Lindgren JU, DeLuca HF Antirachitic activity of 1alpha-hydroxyergocalciferol and 1alpha-hydroxycholecalciferol in rats. J Nutr 1984, 114(11):2043-2046.
45. 3 in the rat. Proc Soc Exp Biol Med 1985, 178(3):432-436.
46. 2 in patients with hormone refractory prostate cancer. Clin Cancer Res 2002, 8(9):2820-2827.
47. 3 analog (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 1996, 56:3570-3576.
48. 3 is mediated by mutual modulation of receptor expression. Euro J of Can 1998, 34:2119-2125.
49. 3 in human breast cancer cells. Can Res 1988, 48:2734-2739.
50. Gonzales EA, Disthabanchong S, Kowalewski R, Martin KJ Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells. Kidney Int 2002, 61:1627-1634.
51. 3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001, 165:1319-1324.
52. Rozen F, Yang XF, Huynh H, Pollak M Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst 1997, 89:652-656.
53. Rozen F, Pollak M Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analog EB 1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 1999, 15:589-594.
54. 3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 1996, 166:231-239.
55. 3 analoginduced growth inhibition in breast cells. J Cell Physiol 2001, 188:383-393.
56. 3 inhibits angiogenesis in vitro and in vivo. Circ Res 2000, 87(3):214-220.
57. 3 and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143(7):2508-2514.
58. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999, 81(5).
59. Beer TM (personal communication).